|
Combination Chemotherapy Plus Amifostine in Treating Patients With Metastatic or Unresectable Cancer Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, trips or professional assistance with a real medical doctor. We aren't docs. Always confer with your doctor about Combination Chemotherapy Plus Amifostine in Treating Patients With Metastatic or Unresectable Cancer conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Combination Chemotherapy Plus Amifostine in Treating Patients With Metastatic or Unresectable Cancer Clinical research trials and Combination Chemotherapy Plus Amifostine in Treating Patients With Metastatic or Unresectable Cancer health trials happen in many of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectualness of new does drugs. The intention of the studies / projects is to figure out particular human healthcare questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to detect cures for all forms of circumstances, like Combination Chemotherapy Plus Amifostine in Treating Patients With Metastatic or Unresectable Cancer. Combination Chemotherapy Plus Amifostine in Treating Patients With Metastatic or Unresectable Cancer Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment options before they are available to the general public. Most times the subjects get treatment for free of charge, and occasionally they are paid for their time. Occasionally there is a cost for a Combination Chemotherapy Plus Amifostine in Treating Patients With Metastatic or Unresectable Cancer clinical trial. Subjects frequently get the best healthcare possible for their Combination Chemotherapy Plus Amifostine in Treating Patients With Metastatic or Unresectable Cancer condition. Hazards are a reality, however, and could include more or frequent mD visits, health risks (possibly life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Combination Chemotherapy Plus Amifostine in Treating Patients With Metastatic or Unresectable Cancer  Combination Chemotherapy Plus Amifostine in Treating Patients With Metastatic or Unresectable Cancer
Combination Chemotherapy Plus Amifostine in Treating Patients With Metastatic or Unresectable Cancer
For Condition: Gastrointestinal Cancer,Head and Neck Cancer,Bone Cancer,Reproductive Cancers,Lung Cancer,Kaposi's Sarcoma,Soft Tissue Sarcoma
Status: No longer recruiting
Sponsor(s): Dana-Farber/Harvard Cancer Center ,
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more that one drug may kill more tumor cells. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus amifostine chemoprotection in treating patients who have metastatic or unresectable cancer and who are undergoing peripheral stem cell transplantation.
Details: OBJECTIVES: I. Describe the toxic effects of ifosfamide, carboplatin, and etoposide (ICE) with amifostine in patients with metastatic or locally unresectable malignancies who are undergoing peripheral stem cell transplantation. II. Describe the pharmacokinetic profile for ifosfamide and its metabolites in patients receiving the maximum tolerated dose of ICE with amifostine. III. Compare the toxic effects of this study with the toxic effects observed on protocol 94-078. IV. Compare the pharmacokinetics of ifosfamide on this study with the pharmacokinetics observed on protocol 94-078. PROTOCOL OUTLINE: Patients undergo peripheral blood stem cell (PBSC) harvest on day -8, followed by ifosfamide IV, carboplatin IV, and etoposide IV (ICE) by 96 hour continuous infusion on days -7 to -4. Patients receive amifostine IV twice a day on days -7 to -3. PBSCs are reinfused on day 0. Filgrastim (G-CSF) is administered subcutaneously beginning on day 0 at least 2 hours after infusion of the stem cells and continuing until blood cell counts recover. Patients are followed monthly for the first 2 months and then for survival. PROJECTED ACCRUAL: A total of 25 evaluable patients will be accrued for this study within 19 months.
Eligibility:
Study Type: Interventional, Educational/Counseling/Training
Minimum Age/Maximum Age: 18 Years/55 Years
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically proven metastatic or locally unresectable malignancy - Patient may be responding to therapy: Stage IIIC/IV or recurrent/refractory ovarian carcinoma (ineligible for other bone marrow or stem cell transplant protocols); Recurrent or refractory germ cell carcinoma; Extensive disease small cell lung cancer in partial or complete remission; Stage IIIB non-small cell lung cancer responding to chemotherapy; Sarcomas in or near complete remission after induction chemotherapy; Responsive bladder, head and neck carcinoma, or carcinoma of unknown primary; Other tumors without curative or first line therapy (not eligible for phase II or III studies) - No active brain or bone marrow metastases --Prior/Concurrent Therapy-- - Biologic therapy: Not specified - Chemotherapy: Greater than 3 weeks since prior chemotherapy; See Disease Characteristics; No other concurrent chemotherapy - Endocrine therapy: Not specified - Radiotherapy: Greater than 1 week since prior radiotherapy; No concurrent radiotherapy - Surgery: Greater than 1 week since prior surgery (except for biopsies) - Other: No barbiturates, dilantin, or cimetidine within 3 weeks of high dose chemotherapy; No antihypertensive medications within 24 hours prior to amifostine administration --Patient Characteristics-- - Age: 18 to 55 - Performance status: PS 0-1 - Life expectancy: Not specified - Hematopoietic: WBC at least 3,000/mm3; Platelet count at least 100,000/mm3 - Hepatic: Bilirubin no greater than 1.5 times upper limit of normal (ULN); SGOT less than 2.5 times ULN - Renal: Creatinine no greater than 1.5 times ULN; Creatinine clearance at least 60 mL/min - Cardiovascular: No uncontrolled or severe cardiovascular disease; No myocardial infarction within 6 months; No congestive heart failure - Other: Not pregnant; No other serious medical or psychological illnesses; No active uncontrolled bacterial, viral, or fungal infection; No active duodenal ulcer
Total Enrollment:
Location and Contact Information:
Overall Study Official:
PaulGuy Richardson, Study Chair, Dana-Farber/Harvard Cancer Center
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114
United States
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115
United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215
United States
Additional Information:
Study ID Numbers: CDR0000066750; DFCI-98068,NCI-V98-1491,ALZA-97-038-ii
Study Start Date: July 1998
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00003657
Other Soft Tissue Sarcoma Studies:
1. Biological Therapy in Treating Patients With Metastatic Cancer
2. Study of S-3304 in Patients with Locally Advanced Non-Small Cell Lung Cancer
3. Study of Inhaled Doxorubicin (Adriamycin) to Treat Advanced Lung Cancer
4. Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer
5. CI-1040 in Treating Patients With Advanced Breast, Colon, Pancreatic, or Non-Small Cell Lung Cancer
Related Studies:
Other Soft Tissue Sarcoma Clinical Trials
Other Massachusetts Clinical Trials
Other Boston Clinical Trials
Combination Chemotherapy Plus Amifostine in Treating Patients With Metastatic or Unresectable Cancer
|
|
|
|
|
|
|
|
